From blood-based diagnostics and durable disease-modifying therapy in Alzheimer’s disease to age-dependent cardiovascular protection with GLP-1 and SGLT2 therapies, this episode captures the most practice-changing advances of 2025. We unpack 10 high-impact updates, including expanded SGLT2 use across the full spectrum of chronic kidney disease, CDC-endorsed twice-yearly injectable HIV prevention, phenotype-driven biologics in COPD, and long-awaited survival gains in small cell lung cancer redefining frontline and relapsed care. Together, these shifts signal a decisive move toward earlier intervention, precision treatment, and trajectory-altering outcomes across major disease states.

From targeted therapies in HER2-mutant lung cancer to the latest Alzheimer’s data with Kisunla, this month’s breakthroughs could reshape patient care. We unpack 10 high-impact studies and trials, including new insights on ILD–cancer links, the HOPE trial in late-window stroke thrombolysis, phenotype-specific benefits of CPAP, and kidney-protective strategies in diabetic CKD. Designed for clinicians, this deep dive blends the latest evidence with real-world clinical implications.

From a once-monthly GLP-1/GIP driving 16% weight loss to a twice-yearly HIV PrEP injection, this episode unpacks the most practice-changing updates in internal medicine. We cover new evidence in obesity care, MASH reversal, stroke anticoagulation timing, sarcoidosis management, COPD biologics, and the cardioprotective power of oral semaglutide. Plus, hear what every rising PGY-2 should know heading into senior year.

From FIT screening outpacing colonoscopy in participation to anti-CD20 drugs showing lasting MS control at 7+ years, this edition brings clarity to complex clinical choices. We examine how metabolic syndrome increases young-onset dementia risk by 24%, why post-ERCP pancreatitis rates haven’t budged in two decades, and the unchanged survival edge between IO and IV access in cardiac arrest.

As phthalates in plastics are linked to 350,000 heart deaths and cannabis use raises dementia odds, we separate correlation from causation. Meanwhile, fecal therapy via colonoscopy proves safe and 95% effective for recurrent C. diff, and FDA expands TAVR for asymptomatic aortic stenosis with a 50% lower risk of death, stroke, or hospitalization.